RT Journal Article
SR Electronic
T1 SARS-CoV-2 infection of the placenta
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.30.20083907
DO 10.1101/2020.04.30.20083907
A1 Hillary Hosier
A1 Shelli Farhadian
A1 Raffaella A. Morotti
A1 Uma Deshmukh
A1 Alice Lu-Culligan
A1 Katherine H. Campbell
A1 Yuki Yasumoto
A1 Chantal B.F. Vogels
A1 Arnau Casanovas-Massana
A1 Pavithra Vijayakumar
A1 Bertie Geng
A1 Camila D. Odio
A1 John Fournier
A1 Anderson F. Brito
A1 Joseph R. Fauver
A1 Feimei Liu
A1 Tara Alpert
A1 Reshef Tal
A1 Klara Szigeti-Buck
A1 Sudhir Perincheri
A1 Christopher Larsen
A1 Aileen M. Gariepy
A1 Gabriela Aguilar
A1 Kristen L. Fardelmann
A1 Malini Harigopal
A1 Hugh S. Taylor
A1 Christian M. Pettker
A1 Anne L. Wyllie
A1 Charles Dela Cruz
A1 Aaron M. Ring
A1 Nathan D. Grubaugh
A1 Albert I. Ko
A1 Tamas L. Horvath
A1 Akiko Iwasaki
A1 Uma M. Reddy
A1 Heather S. Lipkind
YR 2020
UL http://medrxiv.org/content/early/2020/05/07/2020.04.30.20083907.abstract
AB Background The effects of Covid-19 in pregnancy remain relatively unknown. We present a case of second trimester pregnancy with symptomatic Covid-19 complicated by severe preeclampsia and placental abruption.Methods We analyzed placenta for the presence of SARS-CoV-2 through molecular and immunohistochemical assays and by and electron microscopy, and we measured the maternal antibody response in blood to this infection.Results SARS-CoV-2 localized predominantly to syncytiotrophoblast cells at the maternal-fetal interface of the placenta. Histological examination of the placenta revealed a dense macrophage infiltrate, but no evidence for vasculopathy typically associated with preeclampsia.Conclusion This case demonstrates, for the first time, SARS-CoV-2 invasion of the placenta, highlighting the potential for severe morbidity among pregnant women with Covid-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata links in manuscript (sequencing)